Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.  

(Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO)

The clinical trial enrolled 624 patients at 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008).

Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2.

"These data are encouraging," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark.  "We currently have only two drugs to treat influenza, both neuraminidase inhibitors, and resistance is a major concern. There is an urgent need for a new drug with a different mechanism of action for treating influenza."

Data from two other Phase 2 clinical trials, including one clinical trial in children down to 12 months of age, and laboratory studies of the drug's activity against influenza viruses will also be presented at the IDSA meeting.  In total, four different communications will be presented.  The meeting is attended by infectious disease physicians, scientists and public health personnel from the United States and around the world.  

Romark plans to init
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Quebec , Sept. 15, 2014  Valeant Pharmaceuticals ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, ... principal amount of its 6.75% Senior Notes due 2017, ... October 15, 2014 and has mailed an irrevocable notice ... 15, 2014, a copy of the irrevocable notice of ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
... (Nasdaq: ISIS ), the leader in antisense therapeutics, today ... Adams, 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at ... , A live audio webcast of the presentation will be ... Web site, www.isispharm.com . A replay ...
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:9/16/2014)... Registration is now open for the ... 10K, 5K, and 1-mile walk/run to be held on ... Local 338 RWDSU/UFCW, the Town of Babylon, and Island ... of Babylon Town Hall in Lindenhurst, NY. Registration is ... is organized by Hope For The Warriors®, a national ...
(Date:9/16/2014)... Alabama (PRWEB) September 16, 2014 *To find ... AL, visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ... those who qualify:, There is no ... , Compensation may be provided for time ... pneumonia and influenza are the eighth leading cause of death ...
(Date:9/16/2014)... *Anyone who is interested in learning ... FL can visit Avail Clinical Research on the web ... 785-2404. , Why Are Volunteers Needed? , The common ... infecting mankind. While infections may not be as deadly ... more annual visits to the doctor than any other ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... September 16, 2014 BQuick Nutrition is ... of its most popular products - BQuick BURN Clarinol ... educate the general public about the many benefits of ... building lean muscle mass. As well as having a ... benefits, supplement facts, and nutritional information - making it ...
Breaking Medicine News(10 mins):Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 3
... be promising news in the quest to find a ... (ALS), or Lou Gehrigs disease, scientists at the University ... shown that targeting neuronal support cells called astrocytes sharply ... in the laboratory of Don Cleveland, Ph.D., UCSD Professor ...
... to prove anecdotes that canines can smell dangerous drops in ... Irish researchers hope to prove that a dog,s keen sense ... blood sugar levels of diabetics. , Canines have already shown ... helping the physically disabled with daily tasks. , But researchers ...
... found that the gene ENPP1 is linked to preterm ... , Errol Norwitz, M.D., associate professor in the Department ... present preliminary results from this research at the Society ... in Dallas, Texas. , One out of eight babies ...
... Survey says latent infections among immigrants, minorities, poor thwart ... -- It appears that the United States will fall ... according to an analysis of National Health and Nutritional ... of latent TB infection (LTBI) in the U.S. population ...
... February 2, 2008 One-year data from a second ... given every 12 weeks provided sustained, clinically meaningful improvement ... through one year. According to findings presented at ... 87 percent of patients responding to ustekinumab 45 mg ...
... 1 Kristin Davis, star,of US hit TV show ... leading AIDS,activists at a Johannesburg press conference tomorrow, Saturday, ... and AIDS epidemic in,South Africa., (Photo: http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-a ... http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-b ) Kristin, ...
Cached Medicine News:Health News:Targeting astrocytes slows disease progression in ALS 2Health News:Dogs Could Be a Diabetic's Best Friend 2Health News:Dogs Could Be a Diabetic's Best Friend 3Health News:Dogs Could Be a Diabetic's Best Friend 4Health News:Gene linked to preterm birth among Hispanic women 2Health News:U.S. Unlikely to Meet Target for TB Elimination 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 3Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 4Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 2Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: